1
|
Shiraya T, Kure K, Araki F, Kato S, Kaiya T. Correlation between anterior chamber flare changes and diabetic macular edema after intravitreal injection of ranibizumab and aflibercept. Jpn J Ophthalmol 2020; 64:250-256. [PMID: 32108920 DOI: 10.1007/s10384-019-00698-z] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2019] [Accepted: 09/19/2019] [Indexed: 12/19/2022]
Abstract
PURPOSE To evaluate aqueous flare change patterns following anti-vascular endothelial growth factor therapy for diabetic macular edema (DME) and investigate the relationship between changes in flare values and central macular thickness (CMT). STUDY DESIGN Retrospective, interventional case series METHODS: A total of 84 eyes of 62 patients with DME received either intravitreal ranibizumab (IVR; n = 62) or aflibercept (IVA; n = 22). A laser flare photometer (Kowa FM500, Kowa Company, Ltd) was used to measure flare values, and CMT was assessed using optical coherence tomography. Flare values and CMT were measured prior to injection (baseline) and at, 1, 7 and 14 days after injection. RESULTS Flare values in the IVR group decreased significantly at day 14 (P = 0.001), whereas the IVA group showed a significant increase in flare values at day 1 (P < 0.001). In the IVA group, the baseline flare values were significantly higher in the CMT reduction group than in the non-CMT reduction group (P = 0.035). There was no correlation between changes in flare values and CMT either in the IVA or IVR group. CONCLUSIONS Flare value changes in patients treated with IVR decreased at day 14 post-injection. This may indicate when the most anti-inflammatory effect was obtained. There was no correlation between changes in flare values and CMT either in the IVA or IVR group; nevertheless, our research suggests that the baseline flare value is a predictive factor for the efficacy of IVA in DME.
Collapse
Affiliation(s)
- Tomoyasu Shiraya
- Department of Ophthalmology, Graduate School of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan
| | - Kana Kure
- Department of Ophthalmology, Graduate School of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan
| | - Fumiyuki Araki
- Department of Ophthalmology, Graduate School of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan
| | - Satoshi Kato
- Department of Ophthalmology, Graduate School of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
| | | |
Collapse
|
2
|
Jorge EC, Jorge EN, Botelho M, Farat JG, Virgili G, El Dib R. Monotherapy laser photocoagulation for diabetic macular oedema. Cochrane Database Syst Rev 2018; 10:CD010859. [PMID: 30320466 PMCID: PMC6516994 DOI: 10.1002/14651858.cd010859.pub2] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
BACKGROUND Diabetic macular oedema (DMO) is a complication of diabetic retinopathy and one of the most common causes of visual impairment in people with diabetes. Clinically significant macular oedema (CSMO) is the most severe form of DMO. Intravitreal antiangiogenic therapy is now the standard treatment for DMO involving the centre of the macula, but laser photocoagulation is still used in milder or non-central DMO. OBJECTIVES To access the efficacy and safety of laser photocoagulation as monotherapy in the treatment of diabetic macular oedema. SEARCH METHODS We searched CENTRAL, which contains the Cochrane Eyes and Vision Trials Register; MEDLINE; Embase; LILACS; the ISRCTN registry; ClinicalTrials.gov and the WHO ICTRP. The date of the search was 24 July 2018. SELECTION CRITERIA We included randomised controlled trials (RCTs) comparing any type of focal/grid macular laser photocoagulation versus another type or technique of laser treatment and no intervention. We did not compare laser versus other interventions as these are covered by other Cochrane Reviews. DATA COLLECTION AND ANALYSIS We used standard methodological procedures expected by Cochrane. Our primary outcomes were gain or loss of 3 lines (0.3 logMAR or 15 ETDRS letters) of best-corrected visual acuity (BCVA) at one year of follow-up (plus or minus six months) after treatment initiation. Secondary outcomes included final or mean change in BCVA, resolution of macular oedema, central retinal thickness, quality of life and adverse events, all at one year. We graded the certainty of the evidence for each outcome using the GRADE approach. MAIN RESULTS We identified 24 studies (4422 eyes). The trials were conducted in Europe (nine studies), USA (seven), Asia (four) and, Africa (one), Latin America (one), Europe-Asian (one) and Oceania (one). The methodological quality of the studies was difficult to assess as they were poorly reported, so the predominant classification of bias was unclear.At one year, people with DMO receiving laser were less likely to lose BCVA compared with no intervention (risk ratio (RR) 0.42, 95% confidence interval (CI) 0.20 to 0.90; 3703 eyes; 4 studies; I2 = 71%; moderate-certainty evidence). There were also favourable effects observed at two and three years. One study (350 eyes) reported on partial or complete resolution of clinically significant DMO and found moderate-certainty evidence of a benefit at three years with photocoagulation (RR 1.55, 95% CI 1.30 to 1.86). Data on visual improvement, final BCVA, central macular thickness and quality of life were not available. One study related minor adverse effects on the central visual field and another reported one case of iatrogenic premacular fibrosis.Nine studies compared subthreshold versus standard macular photocoagulation (517 eyes). Subthreshold treatment was achieved with different methods of photocoagulation: non-visible conventional (two studies), micropulse (four) or nanopulse (one).Only one small study (29 eyes) reported on improvement or worsening of BCVA and estimates were very imprecise (improvement: RR 0.31, 95% CI 0.01 to 7.09; worsening: RR 0.93, 95% CI 0.15 to 5.76; very low-certainty evidence). All studies reported on continuous BCVA at one year; there was low-certainty evidence of no important difference between subthreshold and standard photocoagulation (mean difference (MD) in logMAR BCVA -0.02, 95% CI -0.07 to 0.03; 385 eyes; 7 studies; I2 = 42%), and were possibly different for different techniques (P = 0.07 and I2 = 61.5% for subgroup heterogeneity), with better results achieved with micropulse photocoagulation (MD -0.08 logMAR, 95% CI -0.16 to 0.0) as compared to the results achieved with nanopulse (MD 0.0 logMAR, 95% CI -0.06 to 0.06) and non-visible conventional (MD 0.04 logMAR, 95% CI -0.03 to 0.11), all of them compared to the standard lasers. One study reported partial to complete resolution of macular oedema at one year. There was low-certainty evidence of some benefit with standard photocoagulation, but estimates of effect were imprecise (RR 0.47, 95% CI 0.21 to 1.03; 29 eyes; 1 study). Studies also reported on the change in central macular thickness at one year and found moderate-certainty evidence of no important difference between subthreshold and standard photocoagulation (MD -9.1 μm, 95% CI -26.2 to 8.0; 385 eyes; 7 studies; I2 = 0%). There were no important adverse effects recorded in the studies.Nine studies compared argon laser versus another type of laser (997 eyes). There was moderate-certainty evidence of a small reduction or no difference between the interventions, with respect to improvement (RR 0.87, 95% CI 0.62 to 1.22; 773 eyes; 6 studies) and worsening of BCVA (RR 0.83, 95% CI 0.57 to 1.21; 773 eyes; 6 studies). Three studies reported few cases of subretinal fibrosis and neovascularization with argon laser and one study found subretinal fibrosis in the krypton group.One study (323 eyes) compared the modified ETDRS (mETDRS) grid technique with the mild macular grid (MMG), which uses mild, widely spaced burns throughout the macula. There was low-certainty evidence of an increased chance of visual improvement with MMG, but the estimate was imprecisely measured and the CIs include an increased risk or decreased risk of visual improvement at one year (RR 1.43, 95% CI 0.56 to 3.65; visual worsening: RR 1.40, 95% CI 0.64 to 3.05; change of logMAR visual acuity: MD -0.04 logMAR, 95% CI -0.01 to 0.09). There was a more significant reduction of central macular thickness with the mETDRS compared to the MMG technique (MD -34.0 µm, -59.8 to -8.3) in the MMG group. The study did not record important adverse effects. AUTHORS' CONCLUSIONS Laser photocoagulation reduces the chances of visual loss and increases those of partial to complete resolution of DMO compared to no intervention at one to three years. Subthreshold photocoagulation, particularly the micropulse technique, may be as effective as standard photocoagulation and RCTs are ongoing to assess whether this minimally invasive technique is preferable to treat milder or non-central cases of DMO.
Collapse
Affiliation(s)
- Eliane C Jorge
- Botucatu Medical School, UNESP ‐ Univ Estadual PaulistaDepartment of Ophthalmology, Otorhinolaryngology and Head and Neck SurgeryDistrito de Rubião Júnior, s/nBotucatuSão PauloBrazil18618‐970
| | - Edson N Jorge
- Botucatu Medical School, UNESP ‐ Univ Estadual PaulistaDepartment of Ophthalmology, Otorhinolaryngology and Head and Neck SurgeryDistrito de Rubião Júnior, s/nBotucatuSão PauloBrazil18618‐970
| | - Mayra Botelho
- Botucatu Medical School, UNESP ‐ Univ Estadual PaulistaDepartment of Internal MedicineBotucatuBrazil
| | - Joyce G Farat
- Botucatu Medical School, UNESP ‐ Univ Estadual PaulistaAvenida Universitária 2766Altos do ParaísoSão PauloBrazil
| | - Gianni Virgili
- University of FlorenceDepartment of Translational Surgery and Medicine, Eye ClinicLargo Brambilla, 3FlorenceItaly50134
| | - Regina El Dib
- Institute of Science and Technology, UNESP ‐ Univ Estadual PaulistaDepartment of Biosciences and Oral DiagnosisSão José dos CamposSPBrazil
| | | |
Collapse
|
3
|
Safety of transfoveal subthreshold diode micropulse laser for fovea-involving diabetic macular edema in eyes with good visual acuity. Retina 2015; 34:2010-20. [PMID: 24837050 DOI: 10.1097/iae.0000000000000177] [Citation(s) in RCA: 66] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
PURPOSE To determine the safety of transfoveal subthreshold diode micropulse laser for fovea-involving diabetic macular edema. METHODS The records of all patients treated with transfoveal subthreshold diode micropulse laser for fovea-involving diabetic macular edema in two retina clinics were reviewed. The eligibility included fovea-involving diabetic macular edema by spectral domain optical coherence tomography and pretreatment visual acuity of 20/40 or better. RESULTS Thirty-nine eyes of 27 patients aged 50 years to 87 years (mean, 69 years) were included. Postoperative follow-up ranged from 3 months to 36 months (mean, 11 months). Fourteen patients were insulin dependent, and 19 had nonproliferative retinopathy. The preoperative visual acuity was 20/20 (10 eyes), 20/25 (10 eyes), 20/30 (8 eyes), and 20/40 (11 eyes). No eye had evidence of laser-induced macular damage by any imaging means postoperatively. There were no adverse treatment effects. Logarithm of the minimum angle of resolution visual acuity was improved on average of 0.03 units at 4 months to 7 months of follow-up (P = 0.0449, paired t-test) and otherwise stable. The central foveal thickness was improved at 4 months to 7 months (P = 0.05, paired t-test) and 8 months to 12 months, postoperatively (P = 0.04, mixed model accounting). Maximum macular thickness was improved at 4 months to 7 months postoperatively (P = 0.01, paired t-test and mixed model accounting). CONCLUSION In a small retrospective series, transfoveal subthreshold diode micropulse laser was safe and effective for the treatment of fovea-involving diabetic macular edema in eyes with good preoperative visual acuity that were not the candidates for conventional photocoagulation or intravitreal injection. Further study is warranted.
Collapse
|
4
|
Subthreshold Micropulse Photocoagulation for Persistent Macular Edema Secondary to Branch Retinal Vein Occlusion including Best-Corrected Visual Acuity Greater Than 20/40. J Ophthalmol 2014; 2014:251257. [PMID: 25276413 PMCID: PMC4167817 DOI: 10.1155/2014/251257] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2014] [Revised: 08/19/2014] [Accepted: 08/20/2014] [Indexed: 12/02/2022] Open
Abstract
To assess the efficacy of subthreshold micropulse diode laser photocoagulation (SMDLP) for persistent macular edema secondary to branch retinal vein occlusion (BRVO), including best-corrected visual acuity (BCVA) > 20/40, thirty-two patients (32 eyes) with macular edema secondary to BRVO were treated by SMDLP. After disease onset, all patients had been followed for at least 6 months prior to treatment. Baseline Snellen visual acuity was used to categorize the eyes as BCVA ≤ 20/40 (Group I) or BCVA > 20/40 (Group II). Main outcome measures were reduction in central macular thickness (CMT) in optical coherence tomography (OCT) and BCVA at 6 months. In the total subject-pool at 6 months, BCVA had not changed significantly but CMT was significantly reduced. Group I exhibited no significant change in CMT at 3 months but exhibited significant reductions at 6 and 12 months. Group II exhibited a marginally significant reduction in CMT at 3 months and a significant reduction at 6 months. In patients with persistent macular edema secondary to BRVO, SMDLP appears to control macular edema with minimal retinal damage. Our findings suggest that SMDLP is an effective treatment method for macular edema in BRVO patients with BCVA > 20/40.
Collapse
|
5
|
Abstract
CNS neurons change their connectivity to accommodate a changing environment, form memories, or respond to injury. Plasticity in the adult mammalian retina after injury or disease was thought to be limited to restructuring resulting in abnormal retinal anatomy and function. Here we report that neurons in the mammalian retina change their connectivity and restore normal retinal anatomy and function after injury. Patches of photoreceptors in the rabbit retina were destroyed by selective laser photocoagulation, leaving retinal inner neurons (bipolar, amacrine, horizontal, ganglion cells) intact. Photoreceptors located outside of the damaged zone migrated to make new functional connections with deafferented bipolar cells located inside the lesion. The new connections restored ON and OFF responses in deafferented ganglion cells. This finding extends the previously perceived limits of restorative plasticity in the adult retina and allows for new approaches to retinal laser therapy free of current detrimental side effects such as scotomata and scarring.
Collapse
|
6
|
Sivaprasad S, Dorin G. Subthreshold diode laser micropulse photocoagulation for the treatment of diabetic macular edema. Expert Rev Med Devices 2012; 9:189-97. [PMID: 22404779 DOI: 10.1586/erd.12.1] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
Diabetic macular edema (DME) is a sight-threatening complication of diabetic retinopathy, the leading cause of visual loss in the working-age population in the industrialized and emerging world. The standard of care for DME is focal/grid laser photocoagulation, which is proven effective in reducing the risk of vision loss, but inherently destructive and associated with tissue damage and collateral effects. Subthreshold diode laser micropulse photocoagulation is a nondestructive tissue-sparing laser procedure, which, in randomized controlled trials for the treatment of DME, has been found equally effective as conventional photocoagulation. Functional and anatomical outcomes from four independent randomized controlled trials provide level one evidence that vision stabilization/improvement and edema resolution/reduction can be elicited with less or no retinal damage, and with fewer or no complications. This review describes the principles of subthreshold diode laser micropulse photocoagulation, its treatment modalities and clinical outcomes in the context of standard laser treatments and of emerging nonlaser therapies for DME.
Collapse
Affiliation(s)
- Sobha Sivaprasad
- King's College Hospital, Laser and Retinal Research Unit, Denmark Hill, London, SE5 9RS, UK.
| | | |
Collapse
|
7
|
SPECTRAL-DOMAIN OPTICAL COHERENCE TOMOGRAPHY IMAGING OF RETINAL CHANGES AFTER CONVENTIONAL MULTICOLOR LASER, SUBTHRESHOLD MICROPULSE DIODE LASER, OR PATTERN SCANNING LASER THERAPY IN JAPANESE WITH MACULAR EDEMA. Retina 2012; 32:1592-600. [DOI: 10.1097/iae.0b013e3182445386] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
8
|
Koss MJ, Naser H, Sener A, Ackermann H, Al-Sarireh F, Singh P, Koch FH. Combination therapy in diabetic macular oedema and retinal vein occlusion--past and present. Acta Ophthalmol 2012; 90:580-9. [PMID: 20636486 DOI: 10.1111/j.1755-3768.2010.01962.x] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
This paper summarizes the recent evidence for combined therapies in the intravitreal medical treatment of diabetic macular oedema or macular oedema, secondary to retinal vein occlusion. Since the introduction of anti-inflammatory or anti-VEGF drugs combined with or used alternatively to laser, visual acuity can be stabilized or improved in a significant number of patients. However, there is an ongoing debate regarding the safety, efficiency and economic concerns related to these intravitreal monotherapies because they warrant frequent repetition to maintain the clinical effect. In the literature, the combination of photolasercoagulation, intravitreal steroids or VEGF-inhibitors, or both, shows early compelling evidence that some patients may benefit from less retreatment compared to monotherapy. To provide a conceptual and perspective approach for a first-line combined therapy, this paper also summarizes own results of pilot interventional case series of a 1.5 cc core pars plana vitrectomy and intravitreal substitution with balanced salt solution (BSS), 1.25 mg bevacizumab and 8 mg triamcinolone.
Collapse
Affiliation(s)
- Michael J Koss
- Department of Ophthalmology, Goethe-University, Frankfurt/Main, Germany.
| | | | | | | | | | | | | |
Collapse
|
9
|
SELECTIVE RETINAL THERAPY WITH MICROSECOND EXPOSURES USING A CONTINUOUS LINE SCANNING LASER. Retina 2011; 31:380-8. [DOI: 10.1097/iae.0b013e3181e76da6] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
10
|
Li W, Sinclair SH, Xu GT. Effects of intravitreal erythropoietin therapy for patients with chronic and progressive diabetic macular edema. Ophthalmic Surg Lasers Imaging Retina 2010; 41:18-25. [PMID: 20128565 DOI: 10.3928/15428877-20091230-03] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/09/2009] [Indexed: 11/20/2022]
Abstract
BACKGROUND AND OBJECTIVE To determine the effects of intravitreal injections of erythropoietin in eyes with severe, chronic diabetic macular edema, 5 eyes of 5 patients underwent injections of rHuEPO alpha (EPO). PATIENTS AND METHODS All eyes had progressive vision loss and persistent or worsening edema with prior multi-modal treatment. EPO (5U/50 microL) was injected intravitreally every 6 weeks for three doses and followed for an additional 6 weeks with complete ocular examinations, fluorescein angiography, optical coherence tomography (OCT), and central field acuity perimetry. RESULTS Visual acuity of all patients was subjectively improved by 3 or more lines in 3 eyes and 1 line in 2 eyes. Visual acuity improved to a larger extent than anatomic improvement by OCT. Clearing of hard exudates but only minor improvement in leakage on fluorescein angiography was observed. Improvement in vision occurred within 1 week after the first injection and was maintained until the end point of the current case series (at 18 weeks after the first injection). CONCLUSION This case series seems to show a short-term positive response to EPO for a specific group of patients with chronic diabetic macular edema who were unresponsive to currently available therapies.
Collapse
Affiliation(s)
- Weiye Li
- Department of Ophthalmology, Drexel University College of Medicine, 219 N. Broad Street, Philadelphia, PA 19107, USA
| | | | | |
Collapse
|
11
|
Ohkoshi K, Yamaguchi T. Subthreshold micropulse diode laser photocoagulation for diabetic macular edema in Japanese patients. Am J Ophthalmol 2010; 149:133-9. [PMID: 19875091 DOI: 10.1016/j.ajo.2009.08.010] [Citation(s) in RCA: 58] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2009] [Revised: 08/08/2009] [Accepted: 08/11/2009] [Indexed: 11/16/2022]
Abstract
PURPOSE To assess the efficacy and safety of subthreshold micropulse diode laser photocoagulation for diabetic macular edema (ME). DESIGN Prospective, nonrandomized interventional case series. METHODS SETTING Institutional. PATIENTS Thirty-six consecutive diabetic patients (43 eyes) with clinically significant ME and a central macular thickness (CMT) <600 microm by optical coherence tomography. OBSERVATION PROCEDURES Subthreshold micropulse diode laser photocoagulation was done with a 15% duty cycle (0.2 to 0.3 sec; 200 microm) at 50% to 90% of the burn threshold energy. The treated area was monitored on color images for 12 months. MAIN OUTCOME MEASURES CMT, best-corrected visual acuity (BCVA), and total macular volume at 3 months. RESULTS After 3 months, there was a significant reduction of CMT (P = .05, paired t test), but the changes of BCVA and macular volume were not significant. The preoperative CMT, BCVA (logarithm of the minimal angle of resolution; logMAR), and macular volume were 341.8 +/- 119.0 microm, 0.12 +/- 0.20, and 8.763 +/- 1.605 mm(3) respectively, vs 300.7 +/- 124.1 microm, 0.12 +/- 0.21, and 8.636 +/- 1.408 mm(3) at 3 months. CMT decreased significantly from 1 month (P = .015, Friedman test). Visual acuity was improved or maintained within 0.2 logMAR for 12 months in 94.7% of the patients. No obvious laser scars were detected in any patient. CONCLUSIONS In patients with moderate diabetic ME, subthreshold micropulse diode laser photocoagulation controls ME and maintains visual acuity with minimal retinal damage. These findings confirm the efficacy of this method for Japanese patients.
Collapse
Affiliation(s)
- Kishiko Ohkoshi
- Department of Ophthalmology, St Luke's International Hospital, Tokyo, Japan.
| | | |
Collapse
|
12
|
Kotoula MG, Chatzoulis DZ, Tahmitzi S, Tsironi EE. Detection of macular photocoagulation scars with confocal infrared reflection imaging. Ophthalmic Surg Lasers Imaging Retina 2009; 40:385-8. [PMID: 19634743 DOI: 10.3928/15428877-20096030-06] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
BACKGROUND AND OBJECTIVE To study the diagnostic reliability (specificity and sensitivity) of confocal infrared reflection in detecting threshold argon laser photocoagulation scars in the macula. PATIENTS AND METHODS Fifty-six maculae with diabetic macular edema were evaluated by biomicroscopic slit-lamp fundus examination, digital color fundus photography, digital fundus fluorescein angiography, and digital infrared reflection images. Three examiners evaluated whether the eye had undergone any laser photopexy in the macula. RESULTS Sensitivity, specificity, and false-positive and false-negative results were calculated for each method. Fluorescein fundus angiography and infrared imaging, although using different approaches, both detect pigment epithelium changes such as laser scars. It seems that both methods are of equal specificity. On the other hand, both biomicroscopic fundus examination and digital color photography showed poor reliability. CONCLUSION Infrared reflection imaging is an easy, noninvasive method with excellent sensitivity and specificity in detecting photocoagulation scars from previous threshold laser treatment. It may be useful in estimating photocoagulated areas, especially if threshold treatment has been applied.
Collapse
Affiliation(s)
- Maria G Kotoula
- Department of Ophthalmology, University of Thessaly, School of Medicine, Larissa, Greece
| | | | | | | |
Collapse
|
13
|
Abstract
PURPOSE To review the results of transpupillary thermotherapy (TTT) on choroidal neovascular membranes associated with age-related macular degeneration (AMD). MATERIALS AND METHODS 35 eyes of 35 patients with AMD and choroidal neovascularization and exudation were treated with TTT and had fundus photographs and fluorescein angiography (FA) before and at least six months after TTT. 28 eyes had predominantly occult lesions as seen on FA, while 7 demonstrated primarily classic lesions. All were treated with 650mw power or less using the 810 nm diode laser (3000 micron spot, duration of 60 seconds). Visual acuity, lesion size, and amount of subretinal fluid were determined by results of examination and review of photographs and fluorescein angiograms. RESULTS A 50% reduction in subretinal fluid was achieved in 67% of treated eyes overall, with stabilization of vision (less than three lines of visual acuity lost) in 86%. Complications from treatment were infrequent (9%) and involved hemorrhage noted in the region of treatment upon follow-up. CONCLUSION TTT promotes resolution of subretinal fluid and appears to stabilize visual acuity in patients with exudative AMD.
Collapse
Affiliation(s)
- T R Friberg
- Department of Ophthalmology, The Eye & Ear Institute, University of Pittsburgh School of Medicine, 203 Lothrop Street, Room 824, Pittsburgh, PA 15213, USA
| | | | | |
Collapse
|
14
|
Relationships between clinical measures of visual function and anatomic changes associated with bevacizumab treatment for choroidal neovascularization in age-related macular degeneration. Eye (Lond) 2008; 23:453-60. [PMID: 19039333 DOI: 10.1038/eye.2008.349] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
Abstract
PURPOSE This pilot study was undertaken to examine the relationships between clinical measures of visual function and anatomic changes occurring in the eyes treated with bevacizumab for choroidal neovascularization (CNV) due to age-related macular degeneration (AMD). METHODS A retrospective review was conducted for 50 eyes that had been treated with at least three injections of bevicizumab for CNV due to AMD, and followed for at least 6 months. Vision outcomes included best-corrected ETDRS chart acuity, scored by best-line read (ETDRS line) and by total letters read (ETDRS letter), and two measures obtained from central acuity perimetry with 98% Michelson contrast targets, the best acuity within 6 degrees of fixation (BA6 degrees ), and global macular acuity (GMA), representing a weighted average of the acuities thresholded at all intercepts within a 10 degrees radius of fixation. Assessment of anatomic outcomes included fibrosis, atrophy, and subretinal hemorrhage grading on fundus photography, CNV size, pigment epithelial detachment (PED) size and grading of CNV leakage on fluorescein angiography, and central retinal PED, and subretinal fluid (SRF) thickness on optical coherence tomography. RESULTS Logistic regression analysis showed an association between the vision outcomes of EDTRS letter and BA6 degrees with the change in SRF thickness (R (2): 0.47 and 0.35, respectively). The outcome of the vision measurement of GMA was associated with the change in SRF thickness, in CNV thickness, and in CNV fibrosis grade (R (2): 0.34). No association was noted between the outcomes of ETDRS line with the change in any anatomic outcomes. CONCLUSION Acuity perimetry outcomes in this study seemed to offer improved understanding of the relationship between the vision outcomes and the measured anatomic changes. It seemed that neither ocular coherence tomography nor fluorescein angiography alone offered sufficient morphologic markers for prediction of functional outcomes.
Collapse
|
15
|
Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema. Am J Ophthalmol 2008; 145:854-61. [PMID: 18328456 DOI: 10.1016/j.ajo.2007.12.031] [Citation(s) in RCA: 132] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2007] [Revised: 12/22/2007] [Accepted: 12/31/2007] [Indexed: 12/12/2022]
Abstract
PURPOSE To compare the effect of an intravitreal injection of bevacizumab, an anti-vascular endothelial growth factor (VEGF) antibody, with that of triamcinolone acetonide, a corticosteroid for reduction of diabetic macular edema (DME). DESIGN Prospective, comparative interventional case series. METHODS Twenty-eight eyes of 14 patients with bilateral DME participated in this study. In each patient, one eye received an intravitreal injection of 4 mg triamcinolone acetonide and the other eye received 1.25 mg bevacizumab. The clinical course of best-corrected visual acuity (VA) with a logarithm of the minimum angle of resolution chart and averaged foveal thickness using optical coherence tomography was monitored for up to 24 weeks after the injection. RESULTS Before the injection, foveal thickness and VA were 522.3 +/- 91.3 microm and 0.64 +/- 0.28 microm in the triamcinolone-injected eye, and 527.6 +/- 78.8 microm and 0.61 +/- 0.18 microm in the bevacizumab-injected eye, respectively; there was no significant difference between the eyes. One week after the injection, both eyes showed significant regression of macular edema. The triamcinolone-injected eye (342.6 +/- 85.5 microm and 0.33 +/- 0.21 microm) showed significantly better results than the bevacizumab-injected eye (397.6 +/- 103.0 microm and 0.37 +/- 0.17 microm). However, both eyes showed the recurrence of macular edema with time, even at 24 weeks. Triamcinolone (410.4 +/- 82.4 microm and 0.47 +/- 0.25 microm) kept better results than bevacizumab (501.6 +/- 92.5 microm and 0.61 +/- 0.17 microm). CONCLUSIONS With the generally used concentration, intravitreal injection of triamcinolone acetonide showed better results in reducing DME and in the improvement of VA than that of bevacizumab, suggesting that the pathogenesis of DME is not only attributable to VEGF-dependency, but is also attributable to other mechanisms suppressed by corticosteroid.
Collapse
|
16
|
Shimura M, Nakazawa T, Yasuda K, Shiono T, Nishida K. Pretreatment of posterior subtenon injection of triamcinolone acetonide has beneficial effects for grid pattern photocoagulation against diffuse diabetic macular oedema. Br J Ophthalmol 2007; 91:449-54. [PMID: 17077114 PMCID: PMC1994742 DOI: 10.1136/bjo.2006.106336] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/12/2006] [Indexed: 11/04/2022]
Abstract
AIM To prospectively evaluate the efficacy of subtenon injection of triamcinolone acetonide (TA) before laser grid pattern photocoagulation (G-PC) for the treatment of diffuse diabetic macular oedema (DDME). METHODS 42 eyes of 37 consecutive patients with DDME were studied. 1 week before G-PC, 21 eyes received TA subtenon injection, and the other eyes served as control. The clinical course of visual acuity (VA) and foveal thickness (FT) was monitored for up to 24 weeks after G-PC. Mean deviation (MD) of perimetry with 30-2 program on Humphrey Perimeter (Zeiss-Humphrey, Dublin, California, USA) was also measured. The average laser intensity was recorded. RESULTS After TA injection, FT and VA were improved, and subsequent G-PC maintained the improvement for up to 24 weeks without recurrence of diffuse diabetic macular oedema. In contrast, G-PC without TA injection induced transient worsening of FT and VA, then both were gradually improved. At 24 weeks after G-PC, MD in the TA-injected eyes was better than those in control. The required laser intensity in TA-injected eyes was less than that for control. CONCLUSION Subtenon injection of TA prior to G-PC allows for treatment with a lower intensity of laser spots and also prevents the decrease in central visual field sensitivity, all of which have clinical advantages for G-PC.
Collapse
Affiliation(s)
- Masahiko Shimura
- Department of Ophthalmology, NTT East Japan Tohoku Hospital, 2-29-1, Yamato, Wakabayashi, Sendai, Miyagi 984-8560, Japan.
| | | | | | | | | |
Collapse
|
17
|
Sinclair SH. Diabetic retinopathy: the unmet needs for screening and a review of potential solutions. Expert Rev Med Devices 2006; 3:301-13. [PMID: 16681452 DOI: 10.1586/17434440.3.3.301] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Diabetic retinopathy remains the leading cause of severe vision loss and blindness in the developed world, in spite of recognized ocular treatments that are successful at reducing the rate of vision impairment. Retinal photography appears a promising method to perform screening in such a setting utilizing new 45 degrees + retinal cameras that do not require pupil dilation and can be operated by a trained, nonophthalmic technician. Certain developments may make the photography more successful including the conversion to electronic chip camera sensors that allow each picture as it is taken to be immediately projected onto a monitor for evaluation and assessment. Utilizing a nonmydriatic camera, studies of single-field photography through a dilated pupil have demonstrated superior or equal sensitivity to fundus examination by an ophthalmologist in a number of studies. However, photography without pupil dilation, especially in the older age group may result in poor-quality photographs owing to intense bilateral pupil constriction after the first images and also due to the presence of cataracts. Computer analysis of the retinal images allows extraction of quantitative data, not only of the diabetic lesions but also of vascular changes that, up until now, have been impossible by human grading and potentially allows a much more detailed and quantitative evaluation of the progression of retinopathy over time. When success of image processing algorithms is demonstrated for a large number of images taken under screening conditions, the benefits of retinal photography and image processing to provide timely, reliable, quantitative and cost-effective results, will make this the preferred method over physician examination or human grader evaluation of the images.
Collapse
Affiliation(s)
- Stephen H Sinclair
- Ophthalmology, Drexel University School of Medicine, Suite 100, 311 E. Baltimore Avenue, Media, PA 19063, USA.
| |
Collapse
|
18
|
Bandello F, Polito A, Del Borrello M, Zemella N, Isola M. "Light" versus "classic" laser treatment for clinically significant diabetic macular oedema. Br J Ophthalmol 2005; 89:864-70. [PMID: 15965168 PMCID: PMC1772712 DOI: 10.1136/bjo.2004.051060] [Citation(s) in RCA: 48] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
AIM To compare the effectiveness of "light" versus "classic" laser photocoagulation in diabetic patients with clinically significant macular oedema (CSMO). METHODS A prospective randomised pilot clinical trial in which 29 eyes of 24 diabetic patients with mild to moderate non-proliferative diabetic retinopathy (NPDR) and CSMO were randomised to either "classic" or "light" Nd:YAG 532 nm (frequency doubled) green laser. "Light" laser treatment differed from conventional ("classic") photocoagulation in that the energy employed was the lowest capable to produce barely visible burns at the level of the retinal pigment epithelium. Primary outcome measure was the change in foveal retinal thickness as measured by optical coherence tomography (OCT); secondary outcomes were the reduction/elimination of macular oedema on contact lens biomicroscopy and fluorescein angiography, change in visual acuity, contrast sensitivity, and mean deviation in the central 10 degrees visual field. Examiners were masked to patients' treatment. RESULTS 14 eyes were assigned to "classic" and 15 were assigned to "light" laser treatment. At 12 months, seven (50%) of 14 eyes treated with "classic" and six (43%) of 14 eyes treated with "light" laser had a decrease of foveal retinal thickness on OCT (p = 0.79). A comparison of reduction/elimination of oedema, visual improvement, visual loss, change in contrast sensitivity, and mean deviation in the central 10 degrees showed no statistical difference between the groups at 12 months (p>0.05 for all groups). CONCLUSIONS This study suggests that "light" photocoagulation for CSMO may be as effective as "classic" laser treatment, thus supporting the rationale for a larger equivalence trial.
Collapse
Affiliation(s)
- F Bandello
- Department of Ophthalmology, University of Udine, P le S Maria della Misericordia, 33100 Udine, Italy.
| | | | | | | | | |
Collapse
|
19
|
Luttrull JK, Musch DC, Mainster MA. Subthreshold diode micropulse photocoagulation for the treatment of clinically significant diabetic macular oedema. Br J Ophthalmol 2005; 89:74-80. [PMID: 15615751 PMCID: PMC1772486 DOI: 10.1136/bjo.2004.051540] [Citation(s) in RCA: 139] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
AIM To report the visual and clinical outcomes of a pilot study of subthreshold diode micropulse (SDM) laser photocoagulation for clinically significant diabetic macular oedema (CSMO). METHODS The results of infrared (810 nm) SDM laser photocoagulation for CSMO were retrospectively reviewed in 95 eyes of 69 consecutive patients with mild to moderate non-proliferative diabetic retinopathy. The same laser parameters were used for each patient. Only the number of laser applications varied between patients, depending on their macular findings. Primary outcome measures were Snellen visual acuity, fluorescein angiographic leakage, and CSMO status. RESULTS Visual acuity was stable or improved in 85% of treated eyes, with a mean follow up of 12.2 months (range 3-29 months). CSMO decreased in 96% and resolved in 79% of treated eyes. No adverse laser events occurred. No laser lesions were detectable ophthalmoscopically or angiographically after treatment, consistent with calculations based on ANSI Z136.1 laser safety standards suggestive of only histologically detectable tissue effects at the laser exposure levels. No laser scarring was observed during the follow up period. CONCLUSION Subthreshold diode micropulse laser photocoagulation minimises chorioretinal damage in the management of CSMO and demonstrates a beneficial effect on visual acuity and CSMO resolution. Prospective studies are needed to fully evaluate this technique.
Collapse
Affiliation(s)
- J K Luttrull
- Private Practice, 3160 Telegraph Road, Suite 230, Ventura, CA, 93003, USA.
| | | | | |
Collapse
|
20
|
Friberg TR. Infrared micropulsed laser treatment for diabetic macular edema--subthreshold versus threshold lesions. Semin Ophthalmol 2004; 16:19-24. [PMID: 15487694 DOI: 10.1076/soph.16.1.19.4217] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
PURPOSE To assess the effectiveness of subthreshold (invisible after placement) and threshold (barely visible after placement) 810nm laser photocoagulation in the treatment of clinically significant diabetic macular edema. METHODS A grid of subthreshold laser spots was used to treat patients with diabetic edema. Retrospectively, the results of treatment of 20 eyes of 20 patients were compared to the results of treatment of 120 eyes of 120 patients using a grid of threshold laser lesions. RESULTS At six months, 60% of subthreshold treated eyes and 75% of threshold treated eyes showed anatomic resolution of macular edema. Improvement or stabilization of visual acuity was achieved in 85% of threshold or subthreshold treated eyes. CONCLUSION Gentle grid treatment of regions of diabetic macular edema was effective in ameliorating the edema and limiting visual loss. Subthreshold laser was less effective in promoting resolution of edema compared to threshold lesions, though the difference was not significant in this instance.
Collapse
Affiliation(s)
- T R Friberg
- University of Pittsburgh, Eye & Ear Institute, 203 Lothrop Street, Room 824, Pittsburgh, PA 15213, USA.
| |
Collapse
|
21
|
Shimum M, Yasuda K, Nakazawa T, Ota S, Tamai M. Effective Treatment of Diffuse Diabetic Macular Edema by Temporal Grid Pattern Photocoagulation. Ophthalmic Surg Lasers Imaging Retina 2004. [DOI: 10.3928/1542-8877-20040701-03] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|